Literature DB >> 11459467

Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability.

D S Wilbur1, D K Hamlin, M K Chyan, B B Kegley, P M Pathare.   

Abstract

An investigation was conducted in which the stabilities of four structurally different biotin derivatives were assessed with regard to biotinamide bond hydrolysis by the enzyme biotinidase. The biotin derivatives studied contained an extra methylene in the valeric acid chain of biotin (i.e., homobiotin), or contained conjugated amino acids having hydroxymethylene, carboxylate, or acetate functionalities on a methylene alpha to the biotinamide bond. The biotinidase hydrolysis assay was conducted on biotin derivatives that were radioiodinated at high specific activity, and then subjected to diluted human serum at 37 degrees C for 2 h. After incubation, assessment of biotinamide bond hydrolysis by biotinidase was readily achieved by measuring the percentage of radioactivity that did not bind with avidin. As controls, an unsubstituted biotin derivative which is rapidly cleaved by biotinidase and an N-methyl-substituted biotin derivative which is stable to biotinidase cleavage were included in the study. The results indicate that increasing the distance from the biotin ring structure to the biotinamide bond by one methylene only decreases the rate of biotinidase cleavage, but does not block it. The data obtained also indicate that placing a hydroxymethylene, carboxylate, or acetate alpha to the biotinamide bond is effective in blocking the biotinamide hydrolysis reaction. These data, in combination with data previously obtained, which indicate that biotin derivatives containing hydroxymethylene or carboxylate moieties retain the slow dissociation rate of biotin from avidin and streptavidin [Wilbur, D. S., et al. (2000) Bioconjugate Chem. 11, 569-583], strongly support incorporation of these structural features into biotin derivatives being used for in vivo targeting applications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459467     DOI: 10.1021/bc0100096

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

1.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.

Authors:  Steven I Park; Jaideep Shenoi; Shani M Frayo; Donald K Hamlin; Yukang Lin; D Scott Wilbur; Patrick S Stayton; Nural Orgun; Mark Hylarides; Franz Buchegger; Aimee L Kenoyer; Amanda Axtman; Ajay K Gopal; Damian J Green; John M Pagel; Oliver W Press
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

2.  Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).

Authors:  Nicoletta Urbano; Stefano Papi; Mauro Ginanneschi; Rita De Santis; Silvia Pace; Ragnar Lindstedt; Liliana Ferrari; Sunju Choi; Giovanni Paganelli; Marco Chinol
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-06       Impact factor: 9.236

3.  Synthesis of a biotin-derived alkyne for pd-catalyzed coupling reactions.

Authors:  Cesear Corona; Bj K Bryant; Jeffrey B Arterburn
Journal:  Org Lett       Date:  2006-04-27       Impact factor: 6.005

4.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.

Authors:  D Scott Wilbur; Steven I Park; Ming-Kuan Chyan; Feng Wan; Donald K Hamlin; Jaideep Shenoi; Yukang Lin; Shani M Wilbur; Franz Buchegger; Anastasia Pantelias; John M Pagel; Oliver W Press
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

5.  Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Matthew A Perry
Journal:  Bioconjug Chem       Date:  2009-03-18       Impact factor: 4.774

6.  Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.

Authors:  Yawen Li; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert Vessella; D Scott Wilbur
Journal:  Nucl Med Biol       Date:  2020-05-03       Impact factor: 2.408

7.  Evaluation of a Pretargeting Strategy for Molecular Imaging of the Prostate Stem Cell Antigen with a Single Chain Antibody.

Authors:  Lena Tienken; Natascha Drude; Isabell Schau; Oliver H Winz; Achim Temme; Elmar Weinhold; Felix M Mottaghy; Agnieszka Morgenroth
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.